Pfiz­er shelves five mid- and ear­ly-stage pro­grams

Pfiz­er is culling a hand­ful of clin­i­cal pro­grams, in­clud­ing tri­als in can­cer and der­ma­tol­ogy, it an­nounced Tues­day.

The cuts in­clude two Phase II pro­grams, one a top­i­cal PDE4 in­hibitor (PF-07038124) for pso­ri­a­sis and atopic der­mati­tis, and an­oth­er (PF-06730512) in fo­cal seg­men­tal glomeru­loscle­ro­sis, a con­di­tion that can lead to kid­ney fail­ure. It has al­so de­cid­ed to squash three Phase I pro­grams, two of which tar­get­ed non-small cell lung can­cer and an­oth­er in de­vel­op­ment against sol­id tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER